OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
BIVI
BioVie Inc.
Class A Common Stock
1.67
-0.12
-6.70%
Delayed (15 Min) Trade Data: 12:00am 08/12/2025
BioVie Inc.
680 W Nye Lane Suite 201
Carson City, NV 89703
Business Description
BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. The Company began a mid-stage (Phase 2a) clinical trial of BIV201 at the McGuire Research Institute in Richmond, VA in 2017. As of April 2019, all six of the planned patients had been treated with BIV201 therapy and the results were presented to the Food & Drug Administration ("FDA") in July. In October 2019, BioVie submitted a proposed Phase 2b/3 clinical trial protocol to the FDA ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001580149
Fiscal Year End
6/30
Company Officers & Contacts
Terren S. Peizer
CEO
Jonathan Adams
COO, President
Joanne Wendy Kim
CFO
Board of Directors
Richard J Berman
Cuong Do
Steve Gorlin
Dr. Robert Hariri
James Lang
Terren S. Peizer
CEO
Sigmund Rogich
Michael Sherman
Other Company Insiders
Not available
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP750 Third Avenue
New York, NY 10017
Investment Bank
Think Equity17 State Street
Floor 22
New York, NY 10004
Securities Counsel
Loeb & Loeb LLP (NY)345 Park Avenue
New York, NY 10154
Securities Counsel
Brown, Gee & Wenger LLP200 Pringle Ave, Suite 400
Walnut Creek, CA 94596
Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
NV, US, 2013
Employees
4 as of 10/28/2019
Shell
No
Products and Services
Not available
Company Facilities
Not available
Company Notes
Formerly=NanoAntibiotics, Inc. until 8-2016
Nasdaq
Securities
Other BioVie Inc. Securities
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
54.50
Change
0.13 (0.24%)
Bid
0.00
Ask
0.00
Volume
3431
Time
00:00
